摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[1-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine | 607369-43-7

中文名称
——
中文别名
——
英文名称
4-[1-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine
英文别名
4-[1-(4-aminophenyl)imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazol-3-amine
4-[1-(4-aminophenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine化学式
CAS
607369-43-7
化学式
C14H11N7O
mdl
——
分子量
293.288
InChiKey
UNEKLVPWDLAKKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    635.9±65.0 °C(Predicted)
  • 密度:
    1.68±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    22
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    122
  • 氢给体数:
    2
  • 氢受体数:
    7

SDS

SDS:8dafaa4394ffd58709915e6563e5e343
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXO GROUP LTD
    公开号:WO2003080610A1
    公开(公告)日:2003-10-02
    A compound of the formula: (I) and-physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR.3; X2 is N or CR'4; X3 ,is..N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X 2, X,3. and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d formula: (II) wherein X5 is a group selected from N or CR7: and X6, is a group selected from O, S or NR8; X7 and X8; which maybe the same or, different is a group selected from N or CR9; ; X9, is a group selected from O, S or NR8 and X10 is N or CR10 ; X11 , X12 and X13 may be the same or different and selected from a group N or CR11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    化合物的式子为:(I),其生理上可接受的盐和/或N-氧化物,其中,X1为N或CR.3;X2为N或CR'4;X3为N或CR5;X4为N或CR6,但至少其中一个但不超过两个X1、X2、X3和X4代表N。R1是从a、b、c或d组中选择的5-或6-成员杂环基,式子为:(II),其中X5是从N或CR7选择的基团;X6是从O、S或NR8选择的基团;X7和X8可以相同或不同,是从N或CR9选择的基团;X9是从O、S或NR8选择的基团,X10是N或CR10;X11、X12和X13可以相同或不同,是从N或CR11的基团中选择的;制备它们的过程,包含它们的制药组合物以及它们在医学上的用途。
  • Imidazopyridine derivatives as kinase inhibitors
    申请人:Bailey Nicholas
    公开号:US20050197328A1
    公开(公告)日:2005-09-08
    A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X 1 is N or CR 3 ; X 2 is N or CR 4 ; X 3 is N or CR 5 ; X 4 is N or CR 6 . with the proviso that at least one but not more than two of X 1 , X 2 , X 3 and X 4 represents N. R 1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X 5 is a group selected from N or CR 7 and X 6 is a group selected from O, S or NR 8; X 7 and X 8 which may be the same or different is a group selected from N or CR 9; X 9 is a group selected from O, S or NR 8 and X 10 is N or CR 10; X 11 , X 12 and X 13 may be the same or different and selected from a group N or CR 11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.
    式中化合物及其生理上可接受的盐和/或N-氧化物,其中: X1为N或CR3; X2为N或CR4; X3为N或CR5; X4为N或CR6; 但须满足X1、X2、X3和X4中至少一个但不超过两个为N; R1为从a、b、c或d组中选择的5-或6-成员杂环基,其中X5为N或CR7组,X6为O、S或NR8组; X7和X8可以相同或不同,为N或CR9组; X9为O、S或NR8组,X10为N或CR10组; X11、X12和X13可以相同或不同,为N或CR11组; 本发明还涉及其制备方法、包含它们的制药组合物以及它们在医学上的应用。
  • Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors
    申请人:Lee Dennis
    公开号:US20070123561A1
    公开(公告)日:2007-05-31
    Novel inhibitors of Rho-kinases are disclosed.
    本发明揭示了Rho-激酶的新型抑制剂
  • IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS
    申请人:GLAXO GROUP LIMITED
    公开号:EP1490367A1
    公开(公告)日:2004-12-29
  • US7348339B2
    申请人:——
    公开号:US7348339B2
    公开(公告)日:2008-03-25
查看更多